<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531999</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT023</org_study_id>
    <nct_id>NCT00531999</nct_id>
  </id_info>
  <brief_title>Raltegravir Insulin Sensitivity Study</brief_title>
  <official_title>An Open Label Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment With Lopinavir / Ritonavir (400 / 100 mg Twice Daily) or Raltegravir 400 mg Twice Daily in HIV Negative Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to look at the effects of two different HIV medications on the
      body's response to insulin (a hormone that regulates blood sugar levels). This will be done
      using a method called the 'euglycaemic clamp'

      The study will also investigate the effects of these drugs on blood fats and on circulating
      markers in the blood stream related to blood vessels (vascular inflammation markers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo four euglycaemic clamp procedures in order to determine the extent of
      glucose disposal. The first clamp will be performed prior to the commencement of the first
      study drug administration, the second one following two weeks of study drug, the third after
      a two week washout period, prior to commencement of second study drug administration and the
      fourth after two weeks of the second study drug
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in insulin sensitivity by euglycaemic clamp method</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum levels of fasting cholesterol, triglycerides</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.
Raltegravir 400 mg twice daily for the last 14 days of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir then lopinavir/ritonavir</intervention_name>
    <description>raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir then raltegravir</intervention_name>
    <description>lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have documented negative HIV serology by ELISA and P24 antigen

          -  Subjects must be clinically well males aged between 18 to 60 years

          -  Fasting blood glucose, total cholesterol and triglycerides within normal limits

          -  Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)

          -  Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥
             50,000/mm3; hemoglobin ≥ 8.0 g/dL)

          -  Serum amylase ≤ 1.5 × ULN (subjects with serum amylase &gt; 1.5 × ULN will remain
             eligible if pancreatic lipase is ≤ 1.5 × ULN)

          -  Sexually active males must use condoms during the course of the study

          -  Life expectancy ≥ 1 year

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Subjects with a waist hip ratio &gt; 0.97 or BMI &gt; 28 kg/m2 will be excluded

          -  Acute or chronic hepatitis B infection (determined by positive hepatitis B surface
             antigen result at the screening visit)

          -  Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody
             result at the screening visit)

          -  Other metabolic syndrome or disease process in the opinion of the investigator likely
             to cause marked disturbance in glucose and lipid homeostasis including hypertension

          -  Receiving on-going therapy with any of the following:

               -  Metabolically active medications

               -  Any lipid-lowering medication

               -  Hormonal agents (oestrogens or androgens)

               -  Glucocorticoids

               -  Beta-blockers

               -  Thiazide diuretics

               -  Thyroid preparations

               -  Psychotropic agents

               -  Anabolic steroids

               -  Megestrol acetate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greame Moyle</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea &amp; Westminser Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Stephens Centre, Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Graeme Moyle</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Euglycaemic clamp</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

